I figured the mental health subforum would be a good place to share this. Feel free to comment or ask questions.
A relative of mine is about to start on d-cycloserine, as an adjunct to their tranylcypromine prescription, for treatment-resistant major depressive disorder. D-cycloserine is a prescription antibiotic commonly used for TB. It also acts as an NMDA receptor glycine partial agonist. At low doses, it is an NMDAR glycine agonist that can be a treatment for anxiety, OCD, and schizophrenia. At higher doses (~1000mg), d-cycloserine is an NMDAR glycine antagonist that can be used for unipolar and bipolar depression. Other NMDAR glycine partial agonists being researched for depression are GLYX-13 and lanicemine. Antagonizing the glycine site appears to confer similar antidepressant effects to ketamine (a noncompetive NMDA antagonist) without unwanted side effects.
The protocol in a recent trial for d-cycloserine as an adjunct for treatment-resistant MDD will be followed: S1461145712000910a.pdf 122.87KB 28 downloads
The trial showed "Of the 13 [treatment-resistant depression] subjects treated with DCS[D-Cycloserine], 54% had a > 50% HAMD score reduction vs. 15% of the 13 patients randomized to placebo (p=0.039)." The sample size does not give me confidence that this treatment will be efficacious, but d-cycloserine is a much less risky adjunct to tranylcypromine than other options.
In fact, the only study I could find regarding MAOI-cycloserine reactions found that d-cycloserine (at an unspecified dose) potentiates tranylcypromine: http://www.sciencedi...006295265901760. This drug is also available at many pharmacies and can be covered by insurance for "infections".
Edited by Ampamet, 31 December 2013 - 02:01 AM.